Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 12.94 USD 2.54% Market Closed
Market Cap: 1.1B USD
Have any thoughts about
Viridian Therapeutics Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one VRDN stock under the Base Case scenario is 65.12 USD. Compared to the current market price of 12.94 USD, Viridian Therapeutics Inc is Undervalued by 80%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VRDN Relative Value
Base Case
65.12 USD
Undervaluation 80%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3 495.9
P/S
P/S
Price to Sales
3 495.9
vs History
19
vs Industry
2
Median 3Y
1 915.3
Median 5Y
549.4
Industry
6.8
Forward
5 670
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-3.9
Industry
21.9
Forward
-3.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-6.2
Median 5Y
-5.4
Industry
19.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-6.3
Median 5Y
-5.4
Industry
23.4
More Details
1.7
P/B
P/B
Price to Book Value
1.7
vs History
73
vs Industry
44
Median 3Y
2.4
Median 5Y
2.2
Industry
2.4
More Details
1 456.4
EV/S
EV/S
Enterprise Value to Sales
1 456.4
vs History
19
vs Industry
2
Median 3Y
736.1
Median 5Y
326.7
Industry
7.2
Forward
2 362.1
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-1.8
Industry
3.9
Forward
-1.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-1.8
Industry
3.8
Forward
-1.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-2.6
Industry
4.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-2.5
Industry
3.5
More Details
21.5
EV/IC
EV/IC
Enterprise Value to IC
21.5
vs History
55
vs Industry
11
Median 3Y
36.9
Median 5Y
26
Industry
4.4
More Details

Multiples Across Competitors

VRDN Competitors Multiples
Viridian Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Viridian Therapeutics Inc
NASDAQ:VRDN
1.1B USD 3 495.9 -3.4 -1.3 -1.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 448 623 -168 482 -204 590.9 -202 256.3
US
Abbvie Inc
NYSE:ABBV
325B USD 5.7 78.2 15 22.1
US
Amgen Inc
NASDAQ:AMGN
146.5B USD 4.3 24.7 13.5 22.3
US
Gilead Sciences Inc
NASDAQ:GILD
127.6B USD 4.4 21.4 9.4 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.7B USD 10.2 -114 24.2 25.3
US
Epizyme Inc
F:EPE
94.1B EUR 1 987.4 -507.1 -552.2 -537.5
AU
CSL Ltd
ASX:CSL
117.1B AUD 4.9 27.3 16.9 21.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
64.3B USD 4.6 14.3 12.9 14.4
US
Seagen Inc
F:SGT
39.3B EUR 19.1 -58.7 -63.2 -57
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
37.2B USD 15.8 -137.9 -615.3 -308.3
P/S Multiple
Revenue Growth P/S to Growth
US
Viridian Therapeutics Inc
NASDAQ:VRDN
Average P/S: 3 223 106.8
3 495.9
861%
4.1
FR
Pharnext SCA
OTC:PNEXF
35 448 623
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.3
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.4
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
1 987.4
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.6
5%
0.9
US
S
Seagen Inc
F:SGT
19.1
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.8
29%
0.5
P/E Multiple
Earnings Growth PEG
US
Viridian Therapeutics Inc
NASDAQ:VRDN
Average P/E: 33.2
Negative Multiple: -3.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -168 482 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78.2
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.7
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
21.4
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -114 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.1 N/A N/A
AU
CSL Ltd
ASX:CSL
27.3
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.3
7%
2
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -137.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Viridian Therapeutics Inc
NASDAQ:VRDN
Average EV/EBITDA: 15.3
Negative Multiple: -1.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -204 590.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
7%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
18%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -552.2 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.9
14%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -615.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Viridian Therapeutics Inc
NASDAQ:VRDN
Average EV/EBIT: 19.7
Negative Multiple: -1.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 256.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.1
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.3
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.3
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -537.5 N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.4
13%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -308.3 N/A N/A

See Also

Summary
VRDN intrinsic value, competitors valuation, and company profile.
DCF Valuation
VRDN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VRDN stock valuation using valuation multiples.
Wall Street Estimates
VRDN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VRDN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 255,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.